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Nuclear factor-kappaB sensitizes to benzyl
isothiocyanate-induced antiproliferation
in p53-deficient colorectal cancer cells
N Abe1,2, D-X Hou3, S Munemasa1, Y Murata1 and Y Nakamura*,1
Benzyl isothiocyanate (BITC), a dietary isothiocyanate derived from cruciferous vegetables, inhibits the proliferation of colorectal
cancer cells, most of which overexpress β-catenin as a result of mutations in the genes for adenomatous polyposis coli or
mutations in β-catenin itself. Because nuclear factor-κB (NF-κB) is a plausible target of BITC signaling in inflammatory cell models,
we hypothesized that it is also involved in BITC-inhibited proliferation of colorectal cancer cells. siRNA-mediated knockdown of the
NF-κB p65 subunit significantly decreased the BITC sensitivity of human colorectal cancer HT-29 cells with mutated p53 tumor
suppressor protein. Treating HT-29 cells with BITC induced the phosphorylation of IκB kinase, IκB-α and p65, the degradation of
IκB-α, the translocation of p65 to the nucleus and the upregulation of NF-κB transcriptional activity. BITC also decreased β-catenin
binding to a positive cis element of the cyclin D1 promoter and thus inhibited β-catenin-dependent cyclin D1 transcription,
possibly through a direct interaction between p65 and β-catenin. siRNA-mediated knockdown of p65 confirmed that p65 negatively
affects cyclin D1 expression. On the other hand, when human colorectal cancer HCT-116 cells with wild-type p53 were treated with
BITC, translocation of p65 to the nucleus was inhibited rather than enhanced. p53 knockout increased the BITC sensitivity of
HCT-116 cells in a p65-dependent manner, suggesting that p53 negatively regulates p65-dependent effects. Together, these results
identify BITC as a novel type of antiproliferative agent that regulates the NF-κB pathway in p53-deficient colorectal cancer cells.
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Colorectal cancer is the third most common cancer in men and
second in women worldwide.1 Colorectal cancer develops in a
complex, multistep process involving progressive disruption of
the homeostatic mechanisms that control epithelial prolifera-
tion, inflammation and differentiation. One of these disruptions
is activation of theWnt/β-catenin signaling pathway, which has
an essential role in the tumorigenesis of colorectal cancer in
human.2 In the absence of a Wnt signal, cytosolic β-catenin is
normally bound to a β-catenin degradation complex, which
causes it to be phosphorylated and then degraded by the
ubiquitin–proteasome system. The β-catenin degradation
complex is composed of adenomatous polyposis coli (APC),
axin, casein kinase Iα and glycogen synthase kinase 3. In
response to the Wnt signal, β-catenin accumulates in the
cytoplasm and is translocated to the nucleus, where it binds to
T-cell factor (TCF)/lymphoid enhancer factor transcription
factors and regulates the expression of target genes involved
in the proliferation and invasiveness of cancer cells and
angiogenesis.3,4 Loss-of-function mutations in APC or muta-
tions in β-catenin at the phosphorylation site, which are found
in almost all human colorectal cancers, lead to stabilization of
the β-catenin protein and aberrant activation of Wnt/β-catenin
signaling. Accumulation of the overexpressed β-catenin in
nucleus activates the expression of its target genes such as
cyclin D1, which is required for the G1/S transition in the cell
cycle.5 This transition contributes to cell proliferation and
tumorigenesis in colorectal cancers.6–8 Thus, targeting the
β-catenin/cyclin D1 pathway is a promising strategy for
preventing the onset of colorectal cancer.
In addition to β-catenin, a transcriptional factor nuclear
factor-κB (NF-κB) controls the proliferation of epithelial cells by
regulating cyclin D1 expression.9,10 NF-κB regulates a wide
variety of cellular genes involved in immunity, inflammation,
cell proliferation and apoptosis. The p65 subunit of NF-κB is a
potent transcriptional activator and can also directly interact
with DNA.11 NF-κB in the cytosol of resting cells is bound to
and inhibited by IκB-α protein. Various stimuli including tumor
necrosis factor-α and lipopolysaccharide enhance the phos-
phorylation of IκB kinase (IKK), and then phosphorylated IKK
(phospho-IKK) phosphorylates IκB-α and p65. Phosphoryla-
tion of IκB-α at Ser32/36 causes it to disassociate from NF-κB,
leading to its degradation by the ubiquitin–proteasome
system.12 This allows NF-κB to translocate to the nucleus
where it regulates the expression of its target genes.
Phosphorylation of p65 at Ser536 is also an indicator of NF-κB
activation.13 Cross talk between β-catenin and NF-κB has a
significant role in regulating the expression of their target
genes.14–16 For example, p65 is recently reported to inhibit β-
catenin binding on the positive cis element TCF-binding
element0 (TBE0) site of the cyclin D1 promoter and thus its
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transcription.17 Therefore, NF-κB has attracted much attention
as a novel regulator of the β-catenin/cyclin D1 pathway in
colorectal cancer cells.
Isothiocyanates (ITCs), mainly derived from cruciferous
vegetables such as broccoli, wasabi (Japanese horseradish)
and watercress, are highly effective in chemoprevention and
have antitumor activities in vitro and in vivo.18 Dietary
consumption of ITC-containing foods has been inversely
related to the risk of colorectal cancer in human.19 We
previously demonstrated that benzyl ITC (BITC), an ingredient
in papaya,20 inhibits cell proliferation by inducing cell cycle
arrest and apoptosis through the mitogen-activated protein
kinase pathways in human T-lymphocytic leukemia Jurkat
cells.21 In human colorectal cancer cells, BITC also inhibits cell
proliferation by stimulating apoptosis.22 By regulating NF-κB,
BITC reduces inflammation in RAW264.7 murine macro-
phages and reduces migration of MDA-MB-231 human breast
cancer cells.23,24 Although BITC might target NF-κB, it is
unclear whether such targeting regulates colorectal cancer
cell proliferation.
In the present study, we investigated the role of NF-κB in
BITC-inhibited colorectal cancer cell proliferation. Here we
demonstrate that NF-κB sensitizes to BITC-induced antipro-
liferation in human colorectal cancer HT-29 cells. Our results
indicate that BITC inhibits β-catenin-dependent cyclin D1
transcription and cell proliferation by causing p65 to accumu-
late in the nucleus. Furthermore, experiments with two other
colorectal cancer cell lines (HCT-116 p53+/+ and HCT-116
p53−/− ) revealed that p53 tumor suppressor protein nega-
tively regulates the effects of p65 in BITC signaling. This study
provides the evidence showing that NF-κB represents a novel
therapeutic target of the ITC-based prevention of colorectal
cancer with p53 mutation and β-catenin overexpression.
Results
NF-κB sensitizes to antiproliferation by BITC in HT-29
cells. The HT-29 cell line is commonly used as a colorectal
cancer model because it has loss-of-function mutations in
APC.25 An immunoblot analysis showed that the transfection
of HT-29 cells with p65-specific siRNA depleted the p65 level
by 68% compared with control (Figure 1a). BITC dose-
dependently suppressed the viability of HT-29 cells trans-
fected with control siRNA, whereas siRNA-mediated knock-
down of p65 significantly counteracted the antiproliferation
induced by 2.5 and 5 μM BITC but not by 10 μM BITC
(Figure 1b). Lactate dehydrogenase (LDH) release that is
used as an index of cytotoxicity was drastically increased by
the treatment of 410 μM BITC (Figure 1c). These results
indicate that NF-κB has a significant role in cell growth
inhibition, rather than cell death by BITC in human colorectal
cancer cells.
BITC activates NF-κB signaling pathway in HT-29 cells.
As shown in Figure 2a, 5 μM BITC increased the phosphor-
ylation of IKK, IκB-α and p65 (at Ser176/180, Ser32/36 and
Ser536, respectively), whereas a higher concentration of
BITC (25 μM) decreased the phosphorylation of these
residues. Consistently, 1–5 μM BITC significantly increased,
but 25 μM BITC decreased, the nuclear translocation of p65
(Figure 2b). The increases of phospho-IKK and phospho-IκB-α
and the decrease of total IκB-α were time dependent
(Figure 2c). The increase in nuclear p65 was apparent 3 h
post treatment of BITC and peaked at 6 h. In contrast,
sulforaphane (SFN), a naturally occurring aliphatic ITC in
broccoli, at concentrations from 1–25 μM, did not increase the
nuclear p65 level (Figure 2d). These results suggest that not
all ITCs are activators of NF-κB signaling in HT-29 cells.
BITC modulates cyclin D1 transcription by modifying the
promoter binding of β-catenin. Consistent with the effects
of BITC on NF-κB signaling pathway (Figures 2a and b),
1–5 μM BITC significantly increased the transcriptional
activity of NF-κB, whereas 25 μM BITC decreased it
(Figure 3a). At both the mRNA and protein levels, cyclin D1
was decreased by the treatment of BITC at 5 and 25 μM
(Figures 3b and c). Moreover, siRNA-mediated knockdown of
p65 canceled the suppression of cyclin D1 gene expression
by 5 μM BITC (Figure 3d). We also examined the effects of
BITC on mRNA levels of the NF-κB-targeted genes other
Figure 1 Effects of p65 knockdown on antiproliferation by BITC in HT-29 cells. (a) Knockdown of p65 by RNAi in HT-29 cells. HT-29 cells were transfected with control siRNA
or p65 siRNA. Whole-cell lysates were prepared and western blot analysis was performed for p65 and actin. (b) Effects of p65 knockdown on antiproliferation by BITC in HT-29
cells. HT-29 cells were transfected with control siRNA or p65 siRNA and exposed to the indicated concentrations of BITC for 24 h and cell viability was determined by trypan blue
dye exclusion assay. The values represent means± S.D. of three separate experiments (*Po0.05 compared between the indicated groups; Student’s t-test). (c) Cytotoxicity of
BITC to HT-29 cells. HT-29 cells were exposed to the indicated concentrations of BITC for 24 h and cytotoxicity was determined by LDH release assay. Data were analyzed by a
one-way analysis of variance (ANOVA) followed by multiple comparisons among means (Tukey’s HSD) using XLSTAT software (Addinsoft, Paris, France). Different letters above
the bars indicate significant differences among treatments for each compound (Po0.05)
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than cyclin D1. The tendency of the dose-dependent effect of
BITC on c-myc was quite similar to that on cyclin D1, even
though the expression of interferon-γ (IFN-γ) was enhanced
by 2.5 μM BITC (Supplementary Figure 1). The binding of β-
catenin and p65 on the NF-κB binding site was enhanced by
treatment of 5 μM BITC and the β-catenin binding on the
TBE0 site was suppressed by treatment of 5 and 25 μM BITC
(Figure 3f). In addition, 25 μM BITC decreased the nuclear β-
catenin level in HT-29 cells (Figure 3g). Treatment of 5 μM
BITC enhanced the interaction between β-catenin and p65
(Figure 3h). These results suggest that the interference of β-
catenin binding on the TBE0 site by p65 is involved in the
suppression of cyclin D1 gene expression by BITC.
p53 negatively regulates BITC-activated NF-κB signaling
pathway. HCT-116 p53+/+ cells are often used as a color-
ectal cancer model because they overexpress β-catenin.26 In
contrast to HT-29 cells, HCT-116 p53+/+ cells show a
decreased nuclear translocation of p65 in the presence of
2.5–25 μM BITC (Figure 4a), accompanied by a decreased
phosphorylation of IκB-α at Ser32/36 (Supplementary Figure 2).
As the p53 status is one of the differences between these cell
lines, we hypothesized that p53 inhibits the BITC-activated
NF-κB signaling pathway in HCT-116 p53+/+ cells. To test this
hypothesis, we examined whether p53 knockdown changes
the effect of BITC on the nuclear level of p65 in HCT-116
p53+/+ cells. Immunoblot analysis indicated that transfection
of p53-specific siRNA depleted the p53 level by 80% and did
not affect the p65 level (Figure 4b). As shown in Figure 4c,
2.5–10 μM BITC significantly enhanced the nuclear translo-
cation of p65 in p53 siRNA-treated HCT-116 p53+/+ cells but
not in control siRNA-treated cells. We further confirmed the
dependency of BITC-activated NF-κB signaling on p53 status
by using a p53 knockout cell line, HCT-116 p53− /−. As shown
in Figure 5a, 1–5 μM BITC significantly enhanced the nuclear
translocation of p65 in HCT-116 p53− /− cells. We also found
that the basal phosphorylation levels of IκB-α at Ser32/36
and p65 at Ser536 in HCT-116 p53− /− cells were high
compared with those in HCT-116 p53+/+ cells (Figure 5b). The
negative regulating role of p53 in the NF-κB translocation was
also confirmed in other colorectal cancer cells including LoVo
cells (p53 wild type) and, DLD-1 and SW480 cells (p53
mutated) (Figure 5c).
To confirm the idea that p53 negatively regulates the
antiproliferation by BITC in colorectal cancer cells, we
compared the effects of BITC on cyclin D1 expression and
cell viability in HCT-116 p53+/+ and HCT-116 p53− /− cells.
BITC (1–5 μM) significantly decreased cyclin D1 expression in
HCT-116 p53− /− cells (Figure 5d) and significantly decreased
their viability (Figure 5e) relative to HCT-116 p53+/+ cells. At
BITC concentrations 410 μM, the decreases of cyclin D1
expression and cell viability were not significantly different
between HCT-116 p53+/+ and HCT-116 p53− /− cells. More-
over, 77% knockdown of p65 in HCT-116 p53− /− cells (see
Figure 5f) significantly counteracted the antiproliferation
induced by 1–5 μM BITC but not the antiproliferation induced
by 10 μMBITC (Figure 5g). These results strongly suggest that
p53 negatively regulates NF-κB-dependent antiproliferation by
BITC in colorectal cancer cells.
Discussion
The present results demonstrate that NF-κB sensitizes to
BITC-induced antiproliferation in p53-deficient human color-
ectal cancer cells. Knockdown of p65 decreased the BITC
sensitivity of HT-29 (Figure 1b) and HCT-116 p53− /− cells
(Figure 5g). BITC significantly induced the nuclear transloca-
tion of the NF-κB p65 subunit in HT-29 (Figure 2b), HCT-116
p53− /− (Figure 5a), DLD-1 and SW480 cells (Figure 5c).
NF-κB-targeting anticancer agents include nonsteroidal antiin-
flammatory drugs (NSAIDs), such as aspirin. Aspirin has been
reported to inhibit the proliferation of colorectal cancer cells by
inhibitingNF-κB transcriptional activity.27 BITC is a food-derived
compound that is known to regulate the proliferation of
colorectal cancer cells. To our knowledge, this is the first report
that shows its antiproliferation activity is sensitized by NF-κB. In
human lung cancer A549 cells, both BITC and SFN exert their
anticancer effects through binding to tubulin.28 However, in
HT-29 cells, the nuclear translocation of p65 was induced by
BITC (Figure 2b) but not by SFN (Figure 2d). BITC has a higher
hydrophobicity than SFN owing to its aromatic ring,29
which may cause it to target molecules other than tubulin.
Figure 2 Effects of BITC and SFN on the expressions of NF-κB signaling proteins in HT-29 cells. HT-29 cells were treated with BITC or SFN and subjected to western blot
analysis. (a) Whole-cell lysates, p-IKK, IKK, p-IκB-α, IκB-α, p-p65, p65 and actin. Three-hour BITC treatment. (b) Nuclear lysates, p65 and lamin B1. Six-hour BITC treatment.
(c) Whole-cell lysates (upper panel) and nuclear lysates (lower panel), p-IKK, p-IκB-α, IκB-α, actin, p65 and lamin B1. (d) Nuclear lysates, p65 and lamin B1. Six-hour SFN
treatment. The values represent means± S.D. of three separate experiments (*Po0.05 compared with control; Student’s t-test)
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Although further study is needed to clarify the underlying
mechanism, it is noteworthy that regulation of NF-κB depends
on the structure of the ITC.
Although numerous studies have established NF-κB as a
tumor-promoting transcription factor,30 recent studies have
shown that NF-κB can also act as a tumor suppressor.31–34
Because NF-κB activity enhances sensitivity to cytotoxic
chemotherapy in certain cancer cell lines, the two opposing
roles of NF-κB may be explained by the other oncogenic
status.35 For example, as β-catenin is overexpressed in
colorectal cancers and functions as an oncogene, NF-κB
could act as a tumor suppressor in colorectal cancer cells. Low
concentrations of BITC (1–5 μM) increased the transcriptional
activity of NF-κB (Figure 3a), whereas they decreased or did
not affect the expression of genes whose promoters contain
binding sites for β-catenin/TCF and NF-κB: cyclin D15,9,10
Figure 3 Involvement of NF-κB in the regulation of β-catenin-dependent cyclin D1 expression by BITC. (a) Effects of BITC on transcriptional activity of NF-κB in HT-29 cells.
Cells were cotransfected with 1 μg of pNF-κB-Luc and 1 μg of pRL-TK vector for 48 h and treated with BITC for 6 h. After treatment, cells were analyzed using a Dual-Luciferase
Reporter Assay System. The values represent means± S.D. of three separate experiments (*Po0.05 compared with control; Student’s t-test). (b) Effects of BITC on the gene
expression of cyclin D1. HT-29 cells were treated with BITC for 6 h. The mRNA levels of cyclin D1 and β-actin were determined by RT-PCR. The values represent means±S.D. of
three separate experiments (*Po0.05 compared with control; Student’s t-test). (c) Effects of BITC on the protein expression of cyclin D1. HT-29 cells were treated with BITC for
24 h. Whole-cell lysates were prepared and western blot analysis was performed for cyclin D1 and actin. The values represent means±S.D. of three separate experiments
(*Po0.05 compared with control; Student’s t-test). (d) Effects of p65 knockdown on BITC-decreased cyclin D1 gene expression. HT-29 cells were transfected with control siRNA
or p65 siRNA and exposed to 5 μM BITC for 6 h. The mRNA expression of cyclin D1 and β-actin were determined using RT-PCR. (e) Schematic representation of the human
cyclin D1 promoter. NF-κB binding site, TBE0 binding site and their sequences are shown. Small arrows indicate the positions and directions of the PCR primers used for the ChIP
assay. (f) Binding of β-catenin or p65 to the NF-κB binding site and the TBE0 site on cyclin D1 promoter. After treatment with BITC for 6 h, HT-29 cells were cross-linked with 1% of
formaldehyde for ChIP assay. Chromatin fragments were immunoprecipitated with antibodies against β-catenin, p65 or goat IgG (negative control) and the cyclin D1 promoter
regions were amplified by PCR. The values represent means± S.D. of three separate experiments (*Po0.05 compared with control of anti-p65 group and †Po0.05 compared
with control of anti-β-catenin group; Student’s t-test). (g) Effects of BITC on nuclear β-catenin level in HT-29 cells. HT-29 cells were treated with different concentrations of BITC for
6 h. Nuclear lysates were prepared and western blot analysis was performed for β-catenin and lamin B1. (h) Detection of the interaction between β-catenin and p65 using
immunoprecipitation assay. HT-29 cells were treated with BITC for 6 h and immunoprecipitated with antibodies against β-catenin, p65 or goat IgG (negative control). Western blot
analysis was performed for p65 and β-catenin
NF-κB sensitizes to antiproliferation by BITC
N Abe et al
4
Cell Death and Disease
(Figure 3b); c-myc;36,37 or COX-238,39 (Supplementary Figure 1).
To the best of our knowledge, the IFN-γ promoter contains the
binding sites of NF-κB but not that of β-catenin/TCF.40 The
mRNA level of IFN-γ was increased by a low concentration of
BITC (2.5 μM;Supplementary Figure 1). This is consistent with
previous findings that cross talk between β-catenin/TCF and
NF-κB has a pivotal role in regulating the expression of their
targeted genes.14–16 Furthermore, p65-dependent effects of
BITC are not observed in p53-positive cancer cells (Figures
4a,5d and e) and thus are presumably not observed in normal
tissue. As the possibility that BITC-induced NF-κB activation
leads to invasion and metastasis of p53-deficient cancer cells
could not be excluded in this study, further studies are needed
to check the side effects of NF-κB activation.
Inhibiting the β-catenin/cyclin D1 pathway can prevent the
onset of colorectal cancer. Little is known about the
antiproliferating mechanism of the β-catenin targeting antic-
ancer agents other than that it involves reducing the β-catenin
level41 and attenuating the transcriptional activity of β-catenin/
TCF complex.42 p65 was recently shown to repress β-catenin-
dependent cyclin D1 transcription, possibly through a protein–
protein interaction.43 This model proposes that mRNA
expression of cyclin D1 is negatively regulated by p65 through
the interference of β-catenin binding on the TBE0 site.
Consistent with this repression model of p65, 5 μM BITC
enhanced the interaction between β-catenin and p65
(Figure 3h), inhibited the β-catenin binding to the TBE0 site
on the cyclin D1 promoter (Figure 3f) and decreased cyclin D1
expression (Figures 3b and c). On the other hand, at a
concentration of 25 μM, BITC decreased cyclin D1 expression
independently of p65 (Figures 3b and c) possibly by
decreasing the binding of β-catenin to the TBE0 site by
downregulating the expression of nuclear β-catenin (Figures
3f and g). An epidemiological study suggested that patients
with a combination of cyclin D1 A870G polymorphism, low
dietary ITC consumption and high-activity glutathione
S-transferase profile have an increased risk of colorectal
cancer.44 In colorectal cancer model Apc (Min/+) mice,
phenethyl ITC, a dietary ITC with an aromatic ring like BITC,
decreased cyclin D1 expression and polyposis formation but
not β-catenin total expression.45 These findings strongly
support the idea that dietary aromatic ITCs elicit chemopre-
ventive effects, possibly by regulating cyclin D1 expression in
colorectal cancers.
Our data indicate that p53 weakens the inhibition of cyclin
D1 expression and cell proliferation by BITC by blocking the
activation of NF-κB signaling pathway in colorectal cancer
cells. HCT-116 p53+/+ cells have a wild-type p53, whereas the
p53 of HT-29 cells has a loss-of-function mutation at codon
273.46 The present results show that BITC increases the levels
of phospho-IκB-α and nuclear p65 in (p53mutated) HT-29 cells
(Figures 2a and b), whereas both are decreased in HCT-116
p53+/+ cells (Figure 4a and Supplementary Figure 2). We also
found that in HCT-116 cells with p53 knockout, BITC increased
nuclear translocation of p65 (Figure 5a) and decreased cyclin
D1 expression and cell viability (Figures 5d and e). Tumor
suppressor protein p53 has a key role in cellular responses to
DNA damage. p53 inactivates NF-κB signaling by reducing the
catalytic activity of IKK through the inhibition of O-linked β-N-
acetyl glucosamine (O-GlcNAc) modification.47 Thus, p53
might block BITC-activated NF-κB signaling pathway by
inhibiting O-GlcNAc modification of IKK. This idea is also
supported by the observation that the basal phosphorylation
levels of IκB-α at Ser32/36 and p65 at Ser536 in HCT-116
p53− /− cells were much higher than those in HCT-116 p53+/+
cells (Figure 5b). We previously reported that p53 negatively
regulates the cytotoxicity by BITC in normal colorectal
CCD-18Co cells.48 Consistent with this report, we showed in
Figure 5e that HCT-116 p53+/+ cells are more resistant to
antiproliferation by BITC than HCT-116 p53− /− cells. BITC
might decrease phospho-IκB-α level and nuclear p65 level
through the decrease of p-IKK catalytic activity by increasing
Figure 4 Effects of p53 knockdown on nuclear translocation of p65 by BITC in HCT-116 p53+/+ cells. (a) Effects of BITC on nuclear p65 level in HCT-116 p53+/+ cells. HCT-116
p53+/+ cells were treated with the indicated concentrations of BITC for 6 h. Western blot analysis of nuclear lysates was performed for p65 and lamin B1. The values represent
means±S.D. of three separate experiments (*Po0.05 compared with control; Student’s t-test). (b) Knockdown of p53 by RNAi. HCT-116 p53+/+ cells were transfected with
control siRNA or p53 siRNA. Whole-cell lysates were prepared and western blot analysis was performed for p53, p65 and actin. (c) Effects of BITC on nuclear p65 level in p53
siRNA-transfected HCT-116 p53+/+ cells. HCT-116 p53+/+ cells were transfected with control siRNA or p53 siRNA and treated with the indicated concentrations of BITC for 6 h.
Western blot analysis of nuclear lysates was performed for p65 and lamin B1. The values represent means±S.D. of three separate experiments (*Po0.05 compared with control
of p53 siRNA group; Student’s t-test)
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p53 level in p53-positive cells. Taken together, these findings
suggest that p53 is a negative regulator of antiproliferation of
colorectal cancer cells by BITC. In addition, BITC did neither
significantly affect cyclin D1 expression in HCT-116 p53+/+
cells, nor significantly increase their viability, although further
studies are needed to check whether BITC increases cancer
risk in the other p53-positive cell lines and tissues.
Our results also indicate that the antiproliferation effects of
BITC depend on its concentration. NF-κB-dependent anti-
proliferation effects of BITC were only observed at the limited
concentrations (1–5 μM). More than 10 μM of BITC drastically
increased cell death in HT-29 cells (Figure 1c) without NF-κB
dependency on antiproliferation effect (Figure 1b). In a
preliminary study, we also found that 10 and 25 μM of BITC-
induced apoptotic cell death but not necrosis (unpublished
data). These results suggest that low concentrations of BITC
mainly induce cell growth inhibition through an NF-κB-
dependent pathway only in p53-deficient cells, whereas higher
concentrations of BITC induce apoptotic cell death with the
decrease of nuclear NF-κB in both p53-positive and -deficient
cells. Such dose-specific cellular responses to BITC were also
observed in human T-lymphocytic leukemia Jurkat cells; BITC
induced the activation of c-Jun N-terminal kinase at 5 μM, but
not at425 μM49 and induced apoptosis at low concentration
but induced necrosis at high concentration.50 The electrophilic
moiety of BITC is reported to covalently bind to cysteine and
lysine residues in vitro51 and to cysteine residues in vivo28.
The number of species of cellular proteins that are modified by
Figure 5 Effects of p53 deficiency on antiproliferation by BITC in colorectal cancer cells. (a) Effects of BITC on nuclear p65 level in HCT-116 p53− /− cells. HCT-116 p53− /−
cells were treated with the indicated concentrations of BITC for 6 h. Western blot analysis of nuclear lysates was performed for p65 and lamin B1. The values represent
means± S.D. of three separate experiments (*Po0.05 compared with control; Student’s t-test). (b) The basal phosphorylation levels of IκB-α at Ser32/36 and p65 at Ser536 in
HCT-116 p53+/+ and HCT-116 p53− /− cells. Whole-cell lysates of HCT-116 p53+/+ and HCT-116 p53− /− cells were prepared and western blot analysis was performed for
phospho-IκB-α (Ser32/36), IκB-α, phospho-p65 (Ser536) and p65. (c) Effects of BITC on nuclear p65 level in other colorectal cancer cells. Indicated colorectal cancer cell lines
with different p53 statuses were treated with 2.5 μM BITC for 6 h. Western blot analysis of nuclear lysates was performed for p65 and lamin B1. (d) Effects of BITC on the protein
expression of cyclin D1 in HCT-116 p53+/+ and HCT-116 p53− /− cells. Both cells were treated with BITC for 24 h. Whole-cell lysates were prepared and western blot analysis was
performed for cyclin D1 and actin. The values represent means±S.D. of three separate experiments. Data were analyzed by a one-way ANOVA followed by Tukey’s HSD using
XLSTAT software. Different letters above the bars indicate significant differences among treatments for each compound (Po0.05). (e) Effects of BITC on cell viability in HCT-116
p53+/+ and HCT-116 p53− /− cells. Both cells were exposed to different concentrations of BITC for 24 h and cell viability was determined by MTTassay. Data were analyzed by a
one-way ANOVA followed by Tukey’s HSD using XLSTAT software. Different letters above the bars indicate significant differences among treatments for each compound
(Po0.05). (f) Knockdown of p65 by RNAi in HCT-116 p53− /− cells. HCT-116 p53− /− cells were transfected with control siRNA or p65 siRNA. Whole-cell lysates were prepared
and western blot analysis was performed for p65 and actin. (g) Effects of p65 knockdown on antiproliferation by BITC in HCT-116 p53− /− cells. HCT-116 p53− /− cells were
transfected with control siRNA or p65 siRNA and exposed to the indicated concentrations of BITC for 24 h and cell viability was determined by trypan blue dye exclusion assay.
The values represent means±S.D. of three separate experiments (*Po0.05 compared between the indicated groups; Student’s t-test)
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ITCs increases with their increasing concentration.52 There-
fore, high doses of BITC may nonspecifically target various
proteins to inhibit cell proliferation independently of NF-κB
signaling.
In conclusion, we have demonstrated that NF-κB sensitizes
to BITC-induced antiproliferation in p53-deficient colorectal
cancer cells. BITC enhances the interaction between p65 and
β-catenin to block the β-catenin binding to the positive cis
element of the cyclin D1 promoter and then inhibits cyclin D1
expression and cell proliferation. Furthermore, p53 blocks
BITC-induced nuclear translocation of p65 and downregulates
BITC-inhibited cyclin D1 expression and cell proliferation.
Taken together, our results suggest that BITC inhibits
β-catenin-dependent cyclin D1 transcription and cell prolifera-
tion through the nuclear translocation of p65 in human
colorectal cancer cells (Figure 6). Thus, we identify NF-κB
as a novel therapeutic target in p53-deficient colorectal cancer
cells, which contributes to our understanding of the complex
intracellular signaling cascades that regulate cell proliferation.
After consumption of cruciferous vegetables, plasma concen-
trations of ITC metabolites peak at a few μmol/l.53,54 However,
a recent preclinical evaluation revealed that the concentra-
tions of ITCs in the gastric lumina temporally reached 600–
2000 μM after the consumption of broccoli extract.55 Therefore,
the concentrations of BITC used in this study are locally
achievable at the colorectum, but it is unclear whether ITC
metabolites such as ITC-glutathione conjugates have
antiproliferative effects. Further studies are needed to
determine the in vivo effects of ingested ITCs on colorectal
cancer cells, aswell as the primary target to activate the NF-κB
pathway by BITC.
Materials and Methods
Chemicals and antibodies. BITC and SFN were purchased from LKT
Laboratories, Inc. (St. Paul, MN, USA). Antibodies against phosphorylated NF-κB
p65 (phospho-NF-κB p65 and Ser536), phospho-IKKα/β (Ser176/180), phosphory-
lated IκB-α (phospho-IκB-α and Ser32/36) and IKK were purchased from Cell
Signaling Technology, Inc. (Beverly, MA, USA). Protein A/G PLUS-Agarose
Immunoprecipitation reagent, siRNAs for NF-κB p65 and p53, control siRNA, siRNA
transfection medium, siRNA transfection reagent, antibodies against NF-κB p65,
IκB-α, lamin B1, actin, β-catenin and p53 and horseradish peroxidase-linked
antirabbit and antimouse IgGs were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Protease inhibitor cocktail was purchased from Sigma-
Aldrich (St. Louis, MO, USA). McCoy’s 5A, RPMI1640, Leibovitz’s L15 and HamF12
medium, penicillin/streptomycin, Trypan blue stain, Lipofectamine 3000 and Trizol
reagent were purchased from Life technologies (Carlsbad, CA, USA). pNF-κB-Luc
was purchased from Agilent Technologies, Inc. (Santa Clara, CA, USA). pRL-TK
vector and Dual-Luciferase Reporter Assay System were purchased from Promega
(Madison, WI, USA). Fatal bovine serum (FBS) was purchased from Nichirei
Corporation (Tokyo, Japan). Bio-Rad Protein Assay was purchased from Bio-Rad
Laboratories (Hercules, CA, USA). Chemi-Lumi One Super was purchased from
Nakalai Tesque Inc. (Kyoto, Japan). Immobilon-P membrane was purchased from
Merck Millipore (Billerica, MA, USA). M-MLV reverse transcriptase and Taq
polymerase were purchased from Takara Bio Inc. (Shiga, Japan). Salmon sperm
DNA was purchased from BioDynamics Laboratory (Tokyo, Japan). All other
chemicals were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Human colorectal cancer cell lines. HT-29 cells and HCT-116 p53+/+ cells
were obtained from the American Type Culture Collection (Manassas, VA, USA).
HCT-116 p53− /− cells were kindly provided by Dr. Bert Vogelstein (Johns Hopkins
Medical Institute, Baltimore, MD, USA). DLD-1 cells and SW480 cells were obtained
from Tohoku University Cell Resource Center for Biomedical Research (Miyagi,
Japan). LoVo cells were obtained from RIKEN BioResource Center Cell Bank
(Ibaraki, Japan). HT-29, HCT-116 p53+/+ and HCT-116 p53− /− cells were
maintained in McCoy’s 5A medium. DLD-1, SW480 and LoVo cells were maintained
in RPMI1640, Leibovitz’s L15 and HamF12 medium, respectively. All media were
supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin. Cells
were grown at 37 °C in an atmosphere of 95% O2 and 5% CO2. Confluent cells
were exposed to the test compounds (resolved in 0.2% DMSO) in the medium
containing 0.5% FBS.
RNA interference. Cells were cultured in six-well plates (2 × 105 cells/well) in
normal growth medium without antibiotic and transfected with siRNA. Predesigned
siRNAs targeting p65 and p53 or nonspecific control siRNAs were transfected to the
cells according to the manufacturer’s instructions using siRNA transfection medium
and siRNA transfection reagent. After 72-h incubation, cells were assayed using the
appropriate protocol.
Trypan blue dye exclusion assay. Trypan blue dye exclusion assay was
carried out for quantitative analysis of cell viability. Cell suspensions were mixed with
0.4% Trypan blue stain. The total cells and viable cells (cells that excluded blue dye)
were counted using a hemocytometer (Bürker-Türk, Hirschmann Laborgeräte
GmbH & Co. KG, Eberstadt, Germany) under a light microscope.
LDH-release assay. LDH-release assay was carried out for the quantitative
determination of cytotoxicity. Cells were seeded in 96-well plates at a density of
2 × 104 cells/well in culture medium. After incubation, cells were treated with BITC
for 24 h. LDH activity was measured by using an LDH-Cytotoxicity Test Wako, in
accordance with the manufacturer's instructions. The absorbance was measured at
560 nm. Total LDH release (100%) was obtained by the treatment of 0.1%
Tween 20.
Western blot analysis. Cells were washed with ice-cold phosphate-buffered
saline without calcium and magnesium (PBS (-)). Whole-cell lysates were prepared
in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA,
2 mM DTT, 10 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1% SDS and 1% Triton-X-100)
containing protease inhibitor cocktail and left on ice for 20 min. After sonication,
Figure 6 Proposed mechanism for the antiproliferation by BITC. BITC activates
NF-κB signaling pathway. p53 inhibits catalytic activity of IKKβ.47 Lower
concentrations of BITC enhance the interaction between p65 and β-catenin, which
blocks the binding of β-catenin to the TBE0 site (a positive cis element of the cyclin D1
promoter). BITC then inhibits cyclin D1 expression and cell growth in colorectal
cancer cells
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lysates were centrifuged and the supernatant was used as whole-cell lysates. For
preparation of nuclear lysates, cells were suspended with buffer-1 (10 mM HEPES
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 10 mM NaF, 1 mM
Na3VO4 and 1 mM PMSF) containing protease inhibitor cocktail and left on ice for
15 min. After addition with 0.4% NP-40, the mixture was centrifuged at 500 × g for
4 min. Pellets were washed with buffer-1 for three times and suspended with buffer-
2 (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
10 mM NaF, 1 mM Na3VO4 and 1 mM PMSF) containing protease inhibitor cocktail.
The mixture was kept on ice for 15 min. After centrifugation, the supernatant was
used as nuclear lysates. Protein concentration in the supernatant was determined
by the Bio-Rad protein assay. Equal quantities of protein were subjected to SDS-
PAGE and transferred to Immobilon-P membrane. The membranes were blocked
and then incubated with the primary antibody overnight at 4 °C followed by an
appropriate secondary antibody. Secondary antibody binding was visualized using a
Chemi-Lumi One Super. Densitometric analysis of the bands was carried out using
the Image J Software Program (National Institutes of Health, Bethesda, MD, USA).
NF-κB luciferase assay. Cells were cultured in 24-well plates (5 × 104 cells/
well) in normal growth medium and cotransfected with 1 μg of pNF-κB-Luc and 1 μg
of pRL-TK vector (internal control) for 48 h using Lipofectamine 3000 and treated
with BITC for 6 h. After treatment, cells were lysed and analyzed using a Dual-
Luciferase Reporter Assay System.
RT-PCR. Cells were washed with ice-cold PBS (-). Total cellular RNA
was isolated using Trizol reagent according to the manufacturer’s recommendations.
RNA was quantified by measuring absorbance at 260 nm. Total RNA (8 μg) was
reverse transcribed with Oligo dT to cDNA using M-MLV reverse transcriptase.
PCR amplification was then performed with Taq polymerase and specific
primers. Primers used in PCR amplification are as follows: cyclin D1, 5′-TC
AAGTGTGACCGAGACTGC-3′ and 5′-AGAGATGGAAGGGGGAAAGA-3′ (355 bp);
β-actin, 5′-GTCACCCACACTGTGCCCATCTA-3′ and 5′-GCAATGCCAGGGTACAT
GGTGGT-3′ (455 bp). The PCR products were then subjected to agarose gel
electrophoresis (3%), stained with ethidium bromide and photographed. Densito-
metric analysis of the bands was carried out using the Image J Software Program.
MTT assay. MTT assay was carried out for quantitative analysis of cell viability
according to the manufacturer's instructions. Cells were pre-incubated for 24 h in 96-
well plate and treated with BITC for 24 h at 37 °C. MTT solution was added to each
well, and the absorbance was measured at 570 nm after 2-h incubation at 37 °C. The
obtained values were compared with each of the controls incubated with vehicle only.
Immunoprecipitation assay. Whole-cell lysates (800 μg), prepared as
described above, were used for immunoprecipitation for 1 h at 4 °C with β-catenin
antibody, p65 antibody or goat IgG. Following immunoprecipitation, 20 μl Protein A/
G PLUS-Agarose Immunoprecipitation reagents were added and the mixture was
incubated for 2 h at 4 °C. Beads were washed with lysis buffer three times.
Immunoprecipitated proteins were subjected to Western blot analysis.
Chromatin immunoprecipitation (ChIP) assay. Cells were cross-
linked with 1% formaldehyde at 37 °C. Cells were washed with PBS (-) containing
1 mM PMSF and 1 mM protease inhibitor cocktail, lysed with SDS lysis buffer
(50 mM Tris-HCl, 10 mM EDTA, 1% SDS, 1 mM PMSF and 1 mM protease inhibitor
cocktail, pH 8.1) and sheared by sonication. The lysates were centrifuged and the
supernatants were collected. Soluble chromatin was precleared with salmon sperm
DNA and Protein A/G PLUS-Agarose Immunoprecipitation reagent for 30 min and
immunoprecipitated with β-catenin antibody, p65 antibody or goat IgG overnight at
4 °C. Control sample was omitted the inclusion of antibody. Immune complexes were
collected with Protein A/G PLUS-Agarose beads for 2 h and washed once with
low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl and
150 mM NaCl, pH 8.1), once with high-salt buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl and 500 mM NaCl, pH 8.1), once with LiCl buffer
(0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA and 10 mM Tris-HCl, pH
8.1) and twice with TE buffer and extracted with elution buffer (1% SDS, 0.1 M
NaHCO3 and 1 mM DTT). The eluent was added with 200 mM NaCl and heated at
65 °C for 6 h to reverse the formaldehyde cross-linking. After digestion with RNase
and proteinase K, DNA fragments were purified by phenol extraction and ethanol
precipitation. Purified DNA fragments were used as a template for PCR
amplification. The PCR products were then subjected to agarose gel electrophoresis
(5%), stained with ethidium bromide and photographed. Densitometric analysis of
the bands was carried out using the Image J Software Program. Primers used for
ChIP assay are as follows and referred to the previous report43: TBE0 site on cyclin
D1 promoter (−551 to − 433), 5′-GGTCCTCCCCGTCCTTGC-3′ and 5′-TGGCGT
TCTTGGAAATGCG-3′; and NF-κB binding site on cyclin D1 promoter
(−872 to − 782), 5′-GCTTTCCATTCAGAGGTGTGTT-3′ and 5′-GTCAAGGTAGGA
AGGCAGCC-3′.
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